Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 2, 2026

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

MSC immune tolerance in cellular cardiomyoplasty.

Ray Chu-Jeng Chiu1

  • 1Division of Cardiothoracic Surgery, Faculty of Medicine, McGill University, Montreal, Canada. ray.chiu@mcgill.ca

Seminars in Thoracic and Cardiovascular Surgery
|August 19, 2008
PubMed
Summary

Allogeneic mesenchymal stem cells (MSCs) show promise for cardiac repair, but in vivo immune tolerance requires further investigation. Confirming their safety could enable readily available cell therapies for heart conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adult stem cell therapy for heart failure.

Expert opinion on biological therapy·2003
Same author

Optimal vascular delay in cardiomyoplasty following latissimus dorsi muscle isolation in dogs.

Journal of the Formosan Medical Association = Taiwan yi zhi·2002
See all related articles

Area of Science:

  • Regenerative Medicine
  • Immunology
  • Cardiology

Background:

  • Mesenchymal stem cells (MSCs) are being explored for cellular cardiomyoplasty.
  • In vitro studies suggest MSCs possess immune tolerance, but in vivo data remain debated.

Purpose of the Study:

  • To evaluate the potential of allogeneic and xenogeneic mesenchymal stem cells (MSCs) for cellular cardiomyoplasty.
  • To address the ongoing controversies regarding the in vivo immune tolerance of MSCs.

Main Methods:

  • Review of experimental and early clinical observations on MSCs in cardiac repair.
  • Analysis of in vitro and in vivo immune tolerance data for allogeneic and xenogeneic MSCs.

Main Results:

  • Increasing evidence supports the utility of allogeneic and xenogeneic MSCs for cardiac applications.

More Related Videos

Cuff-Free Suture-Based Cervical Model for Secondary Heterotopic Heart Transplantation to Evaluate Donor-Specific Immune Tolerance in Mice
07:34

Cuff-Free Suture-Based Cervical Model for Secondary Heterotopic Heart Transplantation to Evaluate Donor-Specific Immune Tolerance in Mice

Published on: March 13, 2026

Related Experiment Videos

Last Updated: Jul 2, 2026

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

Cuff-Free Suture-Based Cervical Model for Secondary Heterotopic Heart Transplantation to Evaluate Donor-Specific Immune Tolerance in Mice
07:34

Cuff-Free Suture-Based Cervical Model for Secondary Heterotopic Heart Transplantation to Evaluate Donor-Specific Immune Tolerance in Mice

Published on: March 13, 2026

  • Persistent controversies exist regarding the in vivo immune tolerance of MSCs.

    • Conclusions:

    • Confirmation of allogeneic MSC feasibility for cardiomyoplasty has significant clinical implications.
    • Successful allogeneic cell therapy offers convenient "off-the-shelf" options and avoids autologous MSC limitations.